Ayvakit (avapritinib) — United Healthcare

Initial criteria

• Diagnosis of gastrointestinal stromal tumor (GIST)
• AND one of the following:
• Patient has unresectable, recurrent, or metastatic disease after failure on approved therapies (e.g., imatinib, sunitinib, regorafenib, ripretinib)
• OR BOTH of the following:
• Disease is one of the following: unresectable; resectable with significant morbidity; metastatic; recurrent; limited progression; gross residual disease (R2 resection); residual disease with significant morbidity
• Presence of a platelet-derived growth factor receptor alpha (PDGFRA) exon mutation, including exon 18 D842V mutation

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Ayvakit therapy

Approval duration

12 months